18F-Fluoroestradiol

Lavanya Sundararajan, Hannah M. Linden, Jeanne Link, Kenneth Krohn, David A. Mankoff

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Estrogen receptor (ER) expression is an important determinant of breast cancer behavior and is critical for response to endocrine therapies such as tamoxifen and aromatase inhibitors. In current practice, ER expression is determined by assay of biopsy material. In more advanced disease, tissue assay may present practical difficulties and be associated with significant sampling error. This and other considerations motivated the development of ER imaging agents for positron emission tomography (PET), of which the most successful has been 18F-16α-17β-fluoroestradiol (FES). In this review, we highlight aspects of ER biology and the importance of the ER in breast cancer therapy; review the structure and synthesis of FES; describe its kinetics and safety/dosimetry data; and highlight validation studies. Also discussed are early results in patients using FES-PET to localize ER-expressing tumors and associated data pointing toward its accuracy as a predictive assay for breast cancer endocrine therapy. Finally, early data for tumors and sites other than breast cancer are mentioned. Preliminary data strongly point toward potential clinical utility for FES-PET, motivating further validation and future clinical trials with prospective endpoints tested under appropriate regulatory oversight.

Original languageEnglish (US)
Pages (from-to)470-476
Number of pages7
JournalSeminars in Nuclear Medicine
Volume37
Issue number6
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Estrogen Receptors
Positron-Emission Tomography
Breast Neoplasms
Aromatase Inhibitors
Selection Bias
Validation Studies
Tamoxifen
Neoplasms
Therapeutics
Clinical Trials
Biopsy
Safety

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Sundararajan, L., Linden, H. M., Link, J., Krohn, K., & Mankoff, D. A. (2007). 18F-Fluoroestradiol. Seminars in Nuclear Medicine, 37(6), 470-476. https://doi.org/10.1053/j.semnuclmed.2007.08.003

18F-Fluoroestradiol. / Sundararajan, Lavanya; Linden, Hannah M.; Link, Jeanne; Krohn, Kenneth; Mankoff, David A.

In: Seminars in Nuclear Medicine, Vol. 37, No. 6, 11.2007, p. 470-476.

Research output: Contribution to journalArticle

Sundararajan, L, Linden, HM, Link, J, Krohn, K & Mankoff, DA 2007, '18F-Fluoroestradiol', Seminars in Nuclear Medicine, vol. 37, no. 6, pp. 470-476. https://doi.org/10.1053/j.semnuclmed.2007.08.003
Sundararajan, Lavanya ; Linden, Hannah M. ; Link, Jeanne ; Krohn, Kenneth ; Mankoff, David A. / 18F-Fluoroestradiol. In: Seminars in Nuclear Medicine. 2007 ; Vol. 37, No. 6. pp. 470-476.
@article{64b8b5e3bfef4325bd25628245b15ea3,
title = "18F-Fluoroestradiol",
abstract = "Estrogen receptor (ER) expression is an important determinant of breast cancer behavior and is critical for response to endocrine therapies such as tamoxifen and aromatase inhibitors. In current practice, ER expression is determined by assay of biopsy material. In more advanced disease, tissue assay may present practical difficulties and be associated with significant sampling error. This and other considerations motivated the development of ER imaging agents for positron emission tomography (PET), of which the most successful has been 18F-16α-17β-fluoroestradiol (FES). In this review, we highlight aspects of ER biology and the importance of the ER in breast cancer therapy; review the structure and synthesis of FES; describe its kinetics and safety/dosimetry data; and highlight validation studies. Also discussed are early results in patients using FES-PET to localize ER-expressing tumors and associated data pointing toward its accuracy as a predictive assay for breast cancer endocrine therapy. Finally, early data for tumors and sites other than breast cancer are mentioned. Preliminary data strongly point toward potential clinical utility for FES-PET, motivating further validation and future clinical trials with prospective endpoints tested under appropriate regulatory oversight.",
author = "Lavanya Sundararajan and Linden, {Hannah M.} and Jeanne Link and Kenneth Krohn and Mankoff, {David A.}",
year = "2007",
month = "11",
doi = "10.1053/j.semnuclmed.2007.08.003",
language = "English (US)",
volume = "37",
pages = "470--476",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - 18F-Fluoroestradiol

AU - Sundararajan, Lavanya

AU - Linden, Hannah M.

AU - Link, Jeanne

AU - Krohn, Kenneth

AU - Mankoff, David A.

PY - 2007/11

Y1 - 2007/11

N2 - Estrogen receptor (ER) expression is an important determinant of breast cancer behavior and is critical for response to endocrine therapies such as tamoxifen and aromatase inhibitors. In current practice, ER expression is determined by assay of biopsy material. In more advanced disease, tissue assay may present practical difficulties and be associated with significant sampling error. This and other considerations motivated the development of ER imaging agents for positron emission tomography (PET), of which the most successful has been 18F-16α-17β-fluoroestradiol (FES). In this review, we highlight aspects of ER biology and the importance of the ER in breast cancer therapy; review the structure and synthesis of FES; describe its kinetics and safety/dosimetry data; and highlight validation studies. Also discussed are early results in patients using FES-PET to localize ER-expressing tumors and associated data pointing toward its accuracy as a predictive assay for breast cancer endocrine therapy. Finally, early data for tumors and sites other than breast cancer are mentioned. Preliminary data strongly point toward potential clinical utility for FES-PET, motivating further validation and future clinical trials with prospective endpoints tested under appropriate regulatory oversight.

AB - Estrogen receptor (ER) expression is an important determinant of breast cancer behavior and is critical for response to endocrine therapies such as tamoxifen and aromatase inhibitors. In current practice, ER expression is determined by assay of biopsy material. In more advanced disease, tissue assay may present practical difficulties and be associated with significant sampling error. This and other considerations motivated the development of ER imaging agents for positron emission tomography (PET), of which the most successful has been 18F-16α-17β-fluoroestradiol (FES). In this review, we highlight aspects of ER biology and the importance of the ER in breast cancer therapy; review the structure and synthesis of FES; describe its kinetics and safety/dosimetry data; and highlight validation studies. Also discussed are early results in patients using FES-PET to localize ER-expressing tumors and associated data pointing toward its accuracy as a predictive assay for breast cancer endocrine therapy. Finally, early data for tumors and sites other than breast cancer are mentioned. Preliminary data strongly point toward potential clinical utility for FES-PET, motivating further validation and future clinical trials with prospective endpoints tested under appropriate regulatory oversight.

UR - http://www.scopus.com/inward/record.url?scp=34848825649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848825649&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2007.08.003

DO - 10.1053/j.semnuclmed.2007.08.003

M3 - Article

VL - 37

SP - 470

EP - 476

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 6

ER -